Solventum Stock Plummets -7.2% With 5-Day Losing Streak

SOLV: Solventum logo
SOLV
Solventum

Solventum (SOLV) – a healthcare company developing and commercializing critical patient solutions – hit a 5-day losing streak, with cumulative losses over this period amounting to -7.2%. The company’s market cap has crashed by about $1.0 Bil over the last 5 days and currently stands at $13 Bil.

Sustained weakness can be more than noise. It often signals shifting sentiment or deeper concerns. A multi-day losing streak may warn of further downside, or present an opportunity to buy if fundamentals are intact.

But here is the interesting part. You are reading about this -7.2% move after it happened. The market has already priced in the news. To manage individual stock risk before the headlines, you need predictive signals, not notifications. High Quality Portfolio has a risk model designed to manage stock-specific drawdowns better.

Image by sainathdeshmukh from Pixabay

Returns vs S&P 500

Relevant Articles
  1. S&P 500 Stocks Trading At 52-Week Low
  2. Stocks Trading At 52-Week Low
  3. S&P 500 Stocks Trading At 52-Week High
  4. Small Cap Stocks Trading At 52-Week High
  5. Mid Cap Stocks Trading At 52-Week High
  6. Large Cap Stocks Trading At 52-Week High

The following table summarizes the return for SOLV stock vs. the S&P 500 index over different periods, including the current streak:

Return Period SOLV S&P 500
1D -0.4% -0.6%
5D (Current Streak) -7.2% 1.7%
1M (21D) 3.1% 1.4%
3M (63D) 11.5% 11.8%
YTD 2026 -3.4% 9.7%
2025 20.0% 16.4%
2024 23.3%
2023 24.2%

Gains and Losses Streaks: S&P 500 Constituents

There are currently 119 S&P constituents with 3 days or more of consecutive gains and 23 constituents with 3 days or more of consecutive losses.

Consecutive Days # of Gainers # of Losers
3D 35 16
4D 74 3
5D 1 2
6D 9 0
7D or more 0 2
Total >=3 D 119 23

Key Financials for Solventum (SOLV)

Last 2 Fiscal Years:

Metric FY2024 FY2025
Revenues $8.3 Bil $8.3 Bil
Operating Income $1.0 Bil $632.0 Mil
Net Income $479.0 Mil $1.6 Bil

Last 2 Fiscal Quarters:

Metric 2025 FQ4 2026 FQ1
Revenues $2.0 Bil $2.0 Bil
Operating Income $93.0 Mil $79.0 Mil
Net Income $63.0 Mil $13.0 Mil

The losing streak SOLV stock is currently on doesn’t inspire much confidence among investors. In contrast, Trefis High Quality (HQ) Portfolio, with a collection of 30 stocks, has a track record of comfortably outperforming its benchmark that includes all 3 — the S&P 500, S&P mid-cap, and Russell 2000 indices. Why is that? As a group, HQ Portfolio stocks provided better returns with less risk versus the benchmark index; less of a roller-coaster ride, as evident in HQ Portfolio performance metrics.